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Chronic hyperglycemia in diabetes is a major causative factor of free radical generation
which further leads to many secondary diabetic complications via the damage to cellular
proteins, membrane lipids, and nucleic acids. Zinc is an essential trace element in all living
systems and plays a structural role in many proteins and enzymes. Somatostatin is known
to have inhibitory effects on various gastrointestinal functions. Therefore, we determined so-
matostatin protein production and secretion levels, and biochemical and light microscopical
changes following zinc supplementation in the gastrointestinal tract of streptozotocin (STZ)-
diabetic rats. The animals were divided into four groups: Group I: control (untreated) ani-
mals; Group II: control animals given zinc sulfate; Group III: diabetic animals; and Group IV:
diabetic animals given zinc sulfate. Zinc sulfate was given to the animals by gavage at a dai-
ly dose of 100 mg/kg body weight for 60 days. Diabetes was induced by intraperitoneal (i.p.)
injection of STZ in a single dose of 65 mg/kg. For histological studies, stomach and duo-
denum tissues were fixed in Bouin solution and sections stained with Masson’s trichrome
and Periodic-Acid-Schiff. Tissue homogenates were used for protein, lipid peroxidation (LPO),
glutathione (GSH), and nonenzymatic glycosylation (NEG) analyses. Zinc supplementation
to the STZ-diabetic rats revealed the protective effect of zinc on these parameters. Zinc sup-
plementation may contribute to prevent at least some complications of diabetes mellitus.
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I. Introduction
Various substances have recently been utilized to pre-
vent the complications of diabetes mellitus in patients or
animals. Zinc complexes have recently been shown to ex-
hibit insulinomimetic activities and an antioxidant role [1, 6,
8, 12, 26, 32]. Zinc homeostasis is maintained via the gas-
trointestinal tract by the processes of absorption of exoge-
nous zinc and excretion of endogenous zinc [19]. It is report-
ed that supplementation of zinc to STZ diabetic animals
reduces the blood glucose levels [18, 26, 31]. However, the
action mechanism of zinc has yet to be clarified. Zinc sulfate
affects a glucose transporter 4, which is involved in the glu-
cose uptake [32]. Zinc deficiency in diabetics could result
from the hyperglycemia or the impaired intestinal zinc ab-
sorption or increased oxidative stress [9, 14, 15, 17, 25, 28].
Zinc supplementation studies in diabetes are very few and
their results are contradictory. Somatostatin is produced in D
cells and intrinsic neurons of the stomach and intestines. It
could directly regulate the secretion of gut hormones and en-
zymes [22]. Somatostatin has been shown to be an effective
inhibitor of insulin [24, 29]. In the present study, we aimed
to investigate somatostatin production and secretion levels,
and biochemical and light microscopical changes following
zinc supplementation in the gastrointestinal tract of STZ-
diabetic rats.
II. Materials and Methods
Animals and tissue preparation
Diabetes was induced by intraperitoneal injection of
STZ in a single dose of 65 mg/kg body weight. STZ was dis-
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solved in a freshly prepared 0.01 M citrate buffer (pH 4.5).
Six–6.5 months old female Swiss albino rats weighing 150–
200 g were used. The experiments were reviewed and ap-
proved by Institute’s Animal Care and Use Committee of the
University of Istanbul. The animals were fed laboratory pel-
let chow and given water ad libitum. All rats were clinically
healthy. The animals were divided into four groups: Group I:
control (untreated) animals (n5); Group II: Control animals
given zinc sulfate (n6); Group III: Diabetic animals (n6);
and Group IV: Diabetic animals given zinc sulfate (n9).
Zinc sulfate was given to the animals by gavage at a daily
dose of 100 mg/kg body weight for 60 days. At the end of
experimental period, stomach (fundus region) and duo-
denum tissues were obtained from animals sacrificed under
ether anesthesia after an overnight fast. Tissue samples were
immediately washed with saline and frozen until needed for
study. For histological studies, stomach and duodenum
tissues were fixed in Bouin solution and sections stained
with Masson’s trichrome and Periodic-Acid-Schiff (PAS).
Biochemical assays
At the end of experimental period, stomach and duo-
denum tissues were homogenized in cold 0.9% serum
physiologic by means of a glass homogenizer to make up
a 10% (w/v) homogenate, centrifuged, and the clear super-
natants used for GSH, LPO, NEG, and protein analysis.
Stomach and duodenum LPO and GSH were determined
by the methods of Ledwozyw et al. [20] and Beutler using
Ellman’s reagent, respectively [3]. Nonenzymatic glycosyl-
ation (NEG) levels were assessed by 2-thiobarbituric acid
[23]. Total protein levels measured by the method of Lowry
using bovine serum albumin as a standard [21].
Immunohistochemistry
Sections were dewaxed and rehydrated. After washing
in phosphate-buffered saline (PBS), sections were immersed
in a solution of 3% H2O2 for 10 min. The sections were then
pre-incubated with non-immune serum for 10 min. After
overnight incubation of the sections in a dilution of the rab-
bit anti-somatostatin antibody (Zymed, San Francisco, CA,
USA) at 4C, specific reactivity was detected with biotiny-
lated second antibody and streptavidin-biotin-peroxidase
complex. The localization of the antigen was indicated by a
red color obtained with 3-amino-9-ethyl-carbazole (AEC) as
chromogen substrate for peroxidase activity. The Histostain
SP kit (Zymed) was used for immunohistochemistry. Detec-
tion procedures were carried out as described by the manu-
facturer. Slides were counterstained with hematoxylin.
The specificity of the immunohistochemical staining was
checked by omission of the primary antibody or by using an
inappropriate antibody. All these controls gave negative
results. Control pancreas sections were used as a positive
control.
Statistical analysis
The biochemical results were statistically evaluated
with SPSS/10 software. Variance analysis was used for com-
parison of the group. One way ANOVA was applied to find
the difference between the groups. Using a post hoc multiple
comparison test, Duncan’s and Scheffe’s multiple range
tests were used to find the significant difference among
means. The mean count of somatostatin-immunoreactive
cells per field of vision by a light microscope was deter-
mined for each animal by averaging the number of cells in
10 randomly selected fields of vision in which the entire
thickness of the mucosa was visible in a single section that
was immunohistochemically stained. The immunoreactivity
was evaluated by two different blinded observers. The sig-
nificance of changes in somatostatin-immunoreactive cells
was evaluated statistically using the Kruskal-Wallis One-
way ANOVA test. Analysis of differences between the con-
trol and experimental groups was performed by using the
Dunn multiple comparison test. Results are expressed as the
meanSD and considered significantly different at the level
of p0.05.
III. Results
Biochemical results
Table 1 shows the content of LPO, GSH, and NEG in
the stomach of normal and experimental groups. In the dia-
betic rats, an increase in stomach LPO levels was observed.
Administration of zinc sulfate was found to reduce stomach
LPO levels in diabetic rats, but in the nondiabetic control
groups, it significantly increased the stomach LPO levels
(ap0.0001). In diabetic rats, a significant decrease in stom-
ach GSH levels was observed when compared with control
group (bp0.0001). In the diabetics rats treated with zinc
sulfate, the stomach GSH levels increased significantly
compared with the diabetic group (cp0.009). In the diabetic
rats, NEG levels were increased significantly when com-
pared with the control group (dp0.0001). In the diabetic
rats treated with zinc sulfate, the stomach NEG levels
decreased significantly when compared with the diabetic
group (ep0.0001).
Table 2 shows the content of LPO and GSH in the
duodenum of normal and experimental groups. In the dia-
betic rats, LPO levels were significantly different between
groups (PANOVA0.0001). In diabetic rats treated with zinc
sulfate, the duodenum LPO levels decreased significantly
when compared with the diabetic group (bp0.0001). The
duodenum GSH levels were significantly reduced in the dia-
betic rats as compared with the control group (p0.0001)
and diabeticzinc sulfate group. In diabetic rats a signifi-
cant decrease in duodenum GSH levels was observed
(cp0.0001). Treatment with zinc sulfate for 60 days was
found to increase in duodenum GSH levels in diabetic rats
(dp0.010). The NEG levels in duodenum tissue were very
low (data not shown).
Light microscopical results
A moderate degree of mucosal hyperemia and cystic
dilatation were observed in fundus of diabetic rats. It was
shown that zinc sulfate treatment moderately improvesEffects of Zinc on Diabetic Rats 11
gastrointestinal damage in the diabeticzinc sulfate group.
Stomach surface and mucous neck cells had dense PAS-pos-
itive material in four groups. Somatostatin-immunoreactive
cells in the four groups were generally found to be scattered
in the neck region of fundic glands (Fig. 1). There was a sig-
nificant difference in somatostatin-immunoreactive cells
between the four groups (PANOVA0.027) (Table 3). Control
group given zinc sulfate was not different from untreated
control group considering somatostatin immunoreactivity. A
significant increase in fundic somatostatin-immunoreactive
cells was observed in diabetic group as compared to controls
(ap0.05). There was no statistically significant change in
fundic somatostatin-immunoreactive cells in the diabetic
zinc sulfate group as compared to the controls. A signifi-
cant decrease was observed in fundic somatostatin immuno-
reactive cells of the diabetic animals given zinc sulfate as
compared to the diabetic animals (bp0.05) (Fig. 1).
Dense positive PAS reaction observed in the duodenal
mucosa was more common in the diabeticzinc sulfate
group as compared to the diabetics. Irregular villi and edema
in lamina propria were observed in significant numbers in
the diabetic rats. But, we observed that zinc sulfate treatment
does not improve duodenal damage in the diabeticzinc
sulfate group (Fig. 2). A small but scattered number of
somatostatin-immunoreactive cells in the four groups was
observed mainly at the base of the crypts in the duodenum.
There was a significant difference in somatostatin-immuno-
reactive cells between the four groups (PANOVA0.031)
(Table 3). There was no statistically significant difference in
duodenal somatostatin-immunoreactive cells in the con-
trolzinc sulfate group as compared to the untreated control.
On the other hand, a notable decrease was observed in
duodenal somatostatin-immunoreactive cells of diabetic
group as compared to controls but this was not statistically
significant. There was an insignificant difference in duode-
nal somatostatin-immunoreactive cells in the diabeticzinc
sulfate group as compared to diabetics (p0.81).
Table 1. Mean levels of stomach GSH, LPO, and NEG for all groups
Groups n LPO (nmol MDA/mg protein)* GSH (nmol GSH/mg protein)* NEG (nmol fructose/mg protein)*
Control 5 0.380.06 22.321.06 14.800.87
ControlZinc Sulfate 6 1.440.14a 18.682.62 25.841.37
Diabetic 6 0.560.04 14.560.9b 23.631.05d
DiabeticZinc Sulfate 9 0.530.05 18.672.00c 17.370.88e
PANOVA 0.0001 0.0001 0.0001
* MeanSD, nNumber of animals.
a, b, d p0.0001 versus control group, c p0.009 versus diabetic group, e p0.0001 versus diabetic group.
Table 2. Mean levels of duodenum LPO and GSH for all groups
Groups n LPO (nmol MDA/mg protein)* GSH (nmol GSH/mg protein)*
Control 5 0.420.01 20.721.84
ControlZinc Sulfate 6 0.480.05 18.631.34
Diabetic 6 0.730.14a 13.391.42c
DiabeticZinc Sulfate 9 0.430.06b 17.792.75d
PANOVA 0.0001 0.0001
* MeanSD, nNumber of animals.
a, c p0.0001 versus control group, b p0.0001 versus diabetic group, d p0.010 versus diabetic group.
Table 3. Densities of somatostatin-producing cells for all groups
Groups n Stomach Cell Density* Duodenum Cell Density*
Control 4 116.7545.84 79.0010.89
ControlZinc sulfate 5 156.0096.71 117.2085.03
Diabetic 4 266.7515.94a 59.259.35
DiabeticZinc sulfate 5 96.4025.42b 24.0018.17
PANOVA 0.027 0.031
* MeanSD, nNumber of animals.
a p0.05 versus control group, b p0.05 versus diabetic group.Bolkent et al. 12
Fig. 1. Somatostatin-immunoreactive cells (arrow) are generally seen in the neck region of fundic glands of stomach. A control rat (1, 2), STZ-
diabetic rat (3, 4), and diabetic rat given zinc sulfate (5, 6). Streptavidin-biotin-peroxidase technique (1, 3, 5), magnifications 200, PAS (2, 4, 6)
magnifications 100.Effects of Zinc on Diabetic Rats 13
Fig. 2. Somatostatin-immunoreactive cells (arrow) localized immunohistochemically in duodenum. A control rat (1, 2), STZ-diabetic rat (3, 4),
and diabetic rat given zinc sulfate (5, 6). Streptavidin-biotin-peroxidase technique (1, 3, 5), magnifications 200, PAS (2, 4, 6), magnifications
100.Bolkent et al. 14
IV. Discussion
The zinc requirement of gastrointestinal cells is high,
since undifferentiated cells require zinc for mucosal cell
function, differentiation, growth, and repair. It is suggested
that zinc is protective and enhances epithelial repair in gas-
trointestinal tract [19]. In the diabeticzinc sulfate group, a
certain degree of repair of mucosa was observed in stomach.
However, we observed that zinc sulfate treatment does
not improve duodenal damage in the diabeticzinc sulfate
group. Zinc supplementation to STZ-diabetic rats reduced
blood glucose concentration (data not shown). This obser-
vation indicates that zinc can improve some of the degen-
erative changes induced in the gastrointestinal tract. The
number of fundic somatostatin-immunoreactive cells sig-
nificantly increased in diabetic group when compared to the
other groups. A marked decrease in duodenal somatostatin-
immunoreactive cells was also found in diabetic group.
Therefore, we concluded that somatostatin-immunoreactive
cells are reciprocally related to insulin in diabetic stomach
and duodenum. On the other hand, a notable decrease was
observed in fundic and duodenal somatostatin immunoreac-
tive cells of the diabetic animals given zinc sulfate as com-
pared to the diabetic animals. It is suggested that the expres-
sion of somatostatin-immunoreactive cells is reversed by
treatment with zinc sulfate for 60 days. To our knowledge,
this is the first reported investigation on the relation of zinc
supplementation and somatostatin in the diabetic stomach
and duodenum. Therefore, more research is needed in order
to clarify its useful role in diabetics.
Alterations in the antioxidant enzymes and increased
oxidative damages have been demonstrated in different tis-
sues of diabetic animals. It is suggested that zinc is protec-
tive against oxidative stress and free radical injury [5, 11].
Some investigators [2, 7, 33] reported that zinc deficiency
increased lipid peroxidation. Faure et al. [10] reported that
zinc supplementation decreases in lipid peroxidation and im-
proves glutathione peroxidase activity in diabetic patients.
Oxidative stress is characterized by increased lipid peroxida-
tion. In the diabetic rats, stomach and duodenum LPO levels
were significantly higher than those of the other groups. Sig-
nificant increases in LPO during diabetes show the occur-
rence of oxidative damage in diabetic rats. Increased oxida-
tive stress may cause some of the morphological alterations
occurring during diabetes. In the stomach of the diabetic
zinc sulfate group, LPO and NEG levels decreased as
compared to the diabetic group. In the duodenum of the
diabeticzinc sulfate group, LPO levels also decreased as
compared to the diabetic group. We can say that zinc has
a role in controlling LPO. In this study, zinc supplementa-
tion did not cause important changes in lipid peroxidation in
stomach but decreased its levels in intestine, because intes-
tinal absorption and excretion of zinc in STZ-diabetic rats
may be affected more than stomach.
GSH is one of the most important nonprotein sulfhy-
dryls present in animal cells. Glutathione plays a major
role as a reductant in the oxidation-reduction process [27].
In the diabeticzinc sulfate group, GSH levels significantly
increased as compared to the diabetic group in the stomach
and duodenum. However, the observed increase in gluta-
thione concentration induced by zinc sulfate may not be
enough to complete the protective mechanism in stomach
and duodenum cells. This study showed that zinc improves
the antioxidant defense system, in particular tissue-reduced
glutathione levels. It has been shown that zinc sulfate plays
an important role in the maintenance of GSH. Previous
studies reported that some free radical scavengers, such
as glutathione, can prevent the development of diabetes
induced by STZ in rats [4, 13]. Johnson and Canfield [16]
reported that the amount of zinc excreted by the intestines
was less in the diabetic rats. Abnormalities in excretion or
absorption may be due to the impairment of the oxidative
balance. It is suggested that the long term exposure of tis-
sues to high glucose concentration may be responsible for
accumulation of nonenzymatically glycosylated products
[30]. Increased reactive oxygen species in diabetes may
result from increased generation of nonenzymatically gly-
cated proteins.
In conclusion, zinc supplementation to STZ-induced
diabetic rats revealed the protective effect of zinc on oxida-
tive stress and free radical metabolism. Our results demon-
strate that zinc supplementation on somatostatin-immuno-
reactive cells in the stomach and duodenum has different
effects. All of these data suggest a role for zinc in the protec-
tion of the somatostatin cell against oxidative stress. Zinc
supplementation may be useful in the future care of patients
with diabetes through its antioxidant effect against oxidant
stress.
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